Electrosprayed Polymeric Nanospheres for Enhanced Solubility, Dissolution Rate, Oral Bioavailability and Antihyperlipidemic Activity of Bezafibrate

References

• Aronson JK. 44 - Drugs that affect lipid metabolism In: Aronson JK, editor. Side Effects of Drugs Annual. Vol. 32 Elsevier; 2010:803–826.
   Google Scholar
• Tenenbaum A, Motro M, Fisman EZ. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovasc Diabetol. 2005;4(1):14. doi:10.1186/1475-2840-4-1416168052
   PubMedGoogle Scholar
• Bezafibrate IPB. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation. 2000;102(1):21.10880410
   PubMed Web of Science ®Google Scholar
• Tenenbaum A, Motro M, Fisman EZ, Tanne D, Boyko V, Behar S. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med. 2005;165(10):1154–1160. doi:10.1001/archinte.165.10.115415911729
   PubMedGoogle Scholar
• Monk JP, Todd PA. Bezafibrate. Drugs. 1987;33(6):539–576. doi:10.2165/00003495-198733060-000023301301
   PubMed Web of Science ®Google Scholar
• Bezafibrate IP. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation. 2000;102(1):21–27. doi:10.1161/01.CIR.102.1.2110880410
   PubMed Web of Science ®Google Scholar
• Oliveira M, Silva G, Campos MST. Chemical degradation kinetics of fibrates: bezafibrate, ciprofibrate and fenofibrate. Braz J Pharm Sci. 2016;52(3):545–553. doi:10.1590/s1984-82502016000300019
   Web of Science ®Google Scholar
• Das S, Ray NM, Wan J, Khan A, Chakraborty T, Ray MB. Micropollutants in wastewater: fate and removal processes. Physi Chem Wastewater Treat Res Recovery. 2017;75 InTech.
   Google Scholar
• Dressman J, Butler J, Hempenstall J, Reppas C. The BCS: where do we go from here? Pharm Technol. 2001;25(7):68–77.
   Google Scholar
• Adkins J, Faulds D. Micronised fenofibrate. Drugs. 1997;54(4):615–633. doi:10.2165/00003495-199754040-000079339964
   PubMed Web of Science ®Google Scholar
• Pouton CW. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci. 2006;29(3–4):278–287. doi:10.1016/j.ejps.2006.04.01616815001
   PubMed Web of Science ®Google Scholar
• Goddeeris C, Coacci J, Van den Mooter G. Correlation between digestion of the lipid phase of smedds and release of the anti-HIV drug UC 781 and the anti-mycotic drug enilconazole from smedds. Eur J Pharm Biopharm. 2007;66(2):173–181. doi:10.1016/j.ejpb.2006.10.00517158039
   PubMed Web of Science ®Google Scholar
• Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm. 2000;50(1):47–60. doi:10.1016/S0939-6411(00)00076-X10840192
   PubMed Web of Science ®Google Scholar
• Perrut M, Jung J, Leboeuf F. Enhancement of dissolution rate of poorly-soluble active ingredients by supercritical fluid processes: part I: micronization of neat particles. Int J Pharm. 2005;288(1):3–10. doi:10.1016/j.ijpharm.2004.09.00715607252
   PubMed Web of Science ®Google Scholar
• Joe JH, Lee WM, Park Y-J, et al. Effect of the solid-dispersion method on the solubility and crystalline property of tacrolimus. Int J Pharm. 2010;395(1–2):161–166. doi:10.1016/j.ijpharm.2010.05.02320580799
   PubMed Web of Science ®Google Scholar
• Vasconcelos T, Sarmento B, Costa P. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discovery Today. 2007;12(23–24):1068–1075. doi:10.1016/j.drudis.2007.09.00518061887
   PubMed Web of Science ®Google Scholar
• Shahzad Y, Saeed S, Ghori MU, et al. Influence of polymer ratio and surfactants on controlled drug release from cellulosic microsponges. Int J Biol Macromol. 2018;109:963–970. doi:10.1016/j.ijbiomac.2017.11.08929154881
   PubMed Web of Science ®Google Scholar
• Yousaf AM, Kim DW, Oh Y-K, Yong CS, Kim JO, Choi H-G. Enhanced oral bioavailability of fenofibrate using polymeric nanoparticulated systems: physicochemical characterization and in vivo investigation. Int J Nanomedicine. 2015;10:1819–1830. doi:10.2147/IJN.S7889525784807
   PubMed Web of Science ®Google Scholar
• Yousaf AM, Ramzan M, Shahzad Y, Mahmood T, Jamshaid M. Fabrication and in vitro characterization of fenofibric acid-loaded hyaluronic acid–polyethylene glycol polymeric composites with enhanced drug solubility and dissolution rate. Int J Polym Mater Polym Biomater. 2019;68:510–515. doi:10.1080/00914037.2018.1466137
   Web of Science ®Google Scholar
• Luo C-F, Yuan M, Chen M-S, et al. Pharmacokinetics, tissue distribution and relative bioavailability of puerarin solid lipid nanoparticles following oral administration. Int J Pharm. 2011;410(1–2):138–144. doi:10.1016/j.ijpharm.2011.02.06421392565
   PubMedGoogle Scholar
• Arya N, Chakraborty S, Dube N, Katti DS. Electrospraying: a facile technique for synthesis of chitosan‐based micro/nanospheres for drug delivery applications. J Biomed Mater Res Part B. 2009;88(1):17–31. doi:10.1002/jbm.b.31085
   PubMedGoogle Scholar
• Hong Y, Li Y, Yin Y, Li D, Zou G. Electrohydrodynamic atomization of quasi-monodisperse drug-loaded spherical/wrinkled microparticles. J Aerosol Sci. 2008;39(6):525–536. doi:10.1016/j.jaerosci.2008.02.004
   Web of Science ®Google Scholar
• Ding L, Lee T, Wang C-H. Fabrication of monodispersed Taxol-loaded particles using electrohydrodynamic atomization. J Control Release. 2005;102(2):395–413. doi:10.1016/j.jconrel.2004.10.01115653160
   PubMed Web of Science ®Google Scholar
• Yousaf AM, Mustapha O, Kim DW, et al. Novel electrosprayed nanospherules for enhanced aqueous solubility and oral bioavailability of poorly water-soluble fenofibrate. Int J Nanomedicine. 2016;11:213–221. doi:10.2147/IJN.S9749626834471
   PubMed Web of Science ®Google Scholar
• Bohr A, Kristensen J, Stride E, Dyas M, Edirisinghe M. Preparation of microspheres containing low solubility drug compound by electrohydrodynamic spraying. Int J Pharm. 2011;412(1):59–67. doi:10.1016/j.ijpharm.2011.04.00521511018
   PubMedGoogle Scholar
• Yu D-G, Williams GR, Yang J-H, Wang X, Yang J-M, Li X-Y. Solid lipid nanoparticles self-assembled from electrosprayed polymer-based microparticles. J Mater Chem. 2011;21(40):15957–15961. doi:10.1039/c1jm12720a
   Web of Science ®Google Scholar
• Enayati M, Ahmad Z, Stride E, Edirisinghe M. Size mapping of electric field-assisted production of polycaprolactone particles. J R Soc Interface. 2010;7. doi:10.1098/rsif.2010.0099.focus.
   Web of Science ®Google Scholar
• Trotta M, Cavalli R, Trotta C, Bussano R, Costa L. Electrospray technique for solid lipid-based particle production. Drug Dev Ind Pharm. 2010;36(4):431–438. doi:10.3109/0363904090324181719788405
   PubMed Web of Science ®Google Scholar
• Cavalli R, Bisazza A, Bussano R, et al. Poly (amidoamine)-cholesterol conjugate nanoparticles obtained by electrospraying as novel tamoxifen delivery system. J Drug Deliv. 2011;2011:1–9. doi:10.1155/2011/587604
   Google Scholar
• Pinto Reis C, Neufeld RJ, Ribeiro AJ, Veiga F. Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomedicine. 2006;2(1):8–21. doi:10.1016/j.nano.2005.12.00317292111
   PubMed Web of Science ®Google Scholar
• Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release. 2001;70(1):1–20. doi:10.1016/S0168-3659(00)00339-411166403
   PubMed Web of Science ®Google Scholar
• Chen D, Zhang J, Peng X, et al. Pharmacokinetic study of bezafibrate in rat by high performance liquid chromatography. Lat Am J Pharm. 2016;35(10):2279–2283.
   Web of Science ®Google Scholar
• Shah V, Konecny J, Everett R, McCullough B, Noorizadeh AC, Skelly J. In vitro dissolution profile of water-insoluble drug dosage forms in the presence of surfactants. Pharm Res. 1989;6(7):612–618. doi:10.1023/A:10159097163122798311
   PubMed Web of Science ®Google Scholar
• Toxicology So. Guiding Principles in the Use of Animals in Toxicology. Virginia: Society of Toxicology Reston; 1999 https://www.toxicology.org/pubs/statements/statements.asp. Accessed 1214, 2019.
   Google Scholar
• Mustapha O, Din F, Kim DW, et al. Novel piroxicam-loaded nanospheres generated by the electrospraying technique: physicochemical characterisation and oral bioavailability evaluation. J Microencapsul. 2016;33(4):323–330. doi:10.1080/02652048.2016.118547527188242
   PubMed Web of Science ®Google Scholar
• Strickley RG. Solubilizing excipients in oral and injectable formulations. Pharm Res. 2004;21(2):201–230. doi:10.1023/B:PHAM.0000016235.32639.2315032302
   PubMed Web of Science ®Google Scholar
• Yousaf AM, Zulfiqar S, Shahzad Y, Hussain T, Mahmood T, Jamshaid M. The preparation and physicochemical characterization of eprosartan mesylate-laden polymeric ternary solid dispersions for enhanced solubility and dissolution rate of the drug. Polim Med. 2018;48(2):69–75. doi:10.17219/pim/10297630916494
   PubMedGoogle Scholar
• Yousaf AM, Malik UR, Shahzad Y, Mahmood T, Silymarin-laden HT. PVP-PEG polymeric composite for enhanced aqueous solubility and dissolution rate: preparation and in vitro characterization. J Pharm Anal. 2019;9(1):34–39. doi:10.1016/j.jpha.2018.09.00330740255
   PubMed Web of Science ®Google Scholar
• Taylor L, Zografi G. Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersions. Pharm Res. 1997;14(12):1691–1698. doi:10.1023/A:10121674103769453055
   PubMed Web of Science ®Google Scholar
• Doherty C, York P. Accelerated stability of an X-ray amorphous frusemide-polyvinylpyrrolidone solid dispersion. Drug Dev Ind Pharm. 1989;15(12):1969–1987. doi:10.3109/03639048909052513
   Web of Science ®Google Scholar
• Konno H, Handa T, Alonzo DE, Taylor LS. Effect of polymer type on the dissolution profile of amorphous solid dispersions containing felodipine. Eur J Pharm Biopharm. 2008;70(2):493–499. doi:10.1016/j.ejpb.2008.05.02318577451
   PubMed Web of Science ®Google Scholar
• Gupta P, Kakumanu VK, Bansal AK. Stability and solubility of celecoxib-PVP amorphous dispersions: a molecular perspective. Pharm Res. 2004;21(10):1762–1769. doi:10.1023/B:PHAM.0000045226.42859.b815553220
   PubMed Web of Science ®Google Scholar
• Tanno F, Nishiyama Y, Kokubo H, Obara S. Evaluation of hypromellose acetate succinate (HPMCAS) as a carrier in solid dispersions. Drug Dev Ind Pharm. 2004;30(1):9–17. doi:10.1081/DDC-12002750615000425
   PubMed Web of Science ®Google Scholar
• Shen C-S, Zhou C-R. Investigation of the thermal decomposition kinetics of bezafibrate. J Therm Anal Calorim. 2016;126(2):959–967. doi:10.1007/s10973-016-5565-9
   Web of Science ®Google Scholar